(47) in their study divided the AML patients into three groups based on their NK maturation profile: hypo-maturation group with CD56bright/dim KIRs- CD57-; intermediate group with CD56dim KIRs-/+ CD57-/+ and hyper-maturation group with CD56dim KIRs+ CD57+ profile. The gene discussed is B3GAT1; the disease is acute myeloid leukemia.